Get the Stockscreener App
0.50
8.23%
0.038
After Hours:
.49
-0.01
-2.00%
Glucotrack Inc stock is traded at $0.50, with a volume of 936.71K.
It is up +8.23% in the last 24 hours and down -31.23% over the past month.
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.
See More
Previous Close:
$0.462
Open:
$0.4599
24h Volume:
936.71K
Relative Volume:
0.22
Market Cap:
$3.13M
Revenue:
-
Net Income/Loss:
$-16.89M
P/E Ratio:
-0.0239
EPS:
-20.8847
Net Cash Flow:
$-16.44M
1W Performance:
-23.08%
1M Performance:
-31.23%
6M Performance:
-90.10%
1Y Performance:
+276.51%
1-Day Range:
$0.4311
$0.54
1-Week Range:
$0.4311
$0.6508
52-Week Range:
$0.0927
$15.90
Glucotrack Inc Stock (GCTK) Company Profile
Name
Glucotrack Inc
Sector
Industry
Phone
972 (8) 675-7878
Address
301 RT 17 NORTH, RUTHERFORD
Compare GCTK vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GCTK
Glucotrack Inc
|
0.50 | 2.89M | 0 | -16.89M | -16.44M | -20.88 |
ISRG
Intuitive Surgical Inc
|
438.10 | 155.76B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
147.63 | 40.30B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.78 | 33.13B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
37.01 | 31.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
208.05 | 30.31B | 5.54B | 1.52B | 1.74B | 10.37 |
Glucotrack Inc Stock (GCTK) Latest News
GCTK Stock Price, Quote & Chart | GLUCOTRACK INC (NASDAQ:GCTK) - ChartMill
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Sahm
GlucoTrack Faces Multiple Nasdaq Deficiency Notices, Delisting Risk - TipRanks
Glucotrack receives Nasdaq delisting notice over listing rule deficiencies By Investing.com - Investing.com South Africa
Glucotrack receives Nasdaq delisting notice over listing rule deficiencies - Investing.com
Glucotrack Received Notice of Delisting - TradingView
Glucotrack (GCTK) cited for bid price and equity Nasdaq deficiencies - Stock Titan
Armistice Capital (GCTK) reports 102,115 shares, 4.99% ownership - Stock Titan
Glucotrack Reports Q1 2026 Results and Advances IDE Submission for Implantable Glucose Monitor - Minichart
Glucotrack's 3-Year CGM Aims to Revolutionize Diabetes Management - BriefGlance
TradingKey - tradingkey.com
Glucotrack 1Q Loss/Shr $2.65 >GCTK - Moomoo
Glucotrack Reports Q1 2026 Net Loss of $4.3M, Cash $3.9M, Files IDE for Implantable CBGM - TradingView
Glucotrack, Inc. Q1 2026: Net loss $(4.33M), EPS $(2.65) — 10-Q Summary - TradingView
Glucotrack, Inc. Submits IDE Application to FDA for Implantable Continuous Blood Glucose Monitoring System and Reports Q1 2026 Financial Results - Quiver Quantitative
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
GlucoTrack, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Glucotrack (GCTK) posts Q1 loss as cash tightens and Nasdaq flags delisting - Stock Titan
Glucotrack (NASDAQ: GCTK) Q1 2026 results, IDE filing and cash runway - Stock Titan
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewswire Inc.
GlucoTrack Stock Short Interest Rises to 59.4% - Moomoo
What you need to know before buying GlucoTrack (GCTK) (+0.76%) 2026-05-08Mid Cap Momentum - newser.com
How GlucoTrack (GCTK) maintains its asset base | GCTK: GlucoTrack Q Results Lack Revenue, EPS DataFinancial Summary - newser.com
GlucoTrack Files IDE for Implantable Glucose Monitor - TipRanks
IDE filing advances Glucotrack (NASDAQ: GCTK) implantable glucose monitor - Stock Titan
Glucotrack Submits Blood Glucose Monitoring Technology to FDA - Yahoo Finance
Glucotrack Submits IDE Application for U.S. Clinical Study of Its Implantable Continuous Blood Glucose Monitoring System - citybiz
Glucotrack Submits IDE to FDA for Implantable Continuous Blood Glucose Monitoring System - geneonline.com
Glucotrack submits FDA application for implantable glucose monitor - Investing.com
Glucotrack submits FDA application for implantable glucose monitor By Investing.com - Investing.com Canada
GlucoTrack, Inc. announced it has officially submitted an Investigational Device Exemption (IDE) application to US regulators for its innovative implantable continuous glucose monitoring technology. - Bitget
Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology - The Manila Times
Glucotrack, Inc. Submits Investigational Device Exemption Application to FDA for Continuous Blood Glucose Monitoring Technology - Quiver Quantitative
Implantable diabetes monitor moves toward U.S. trial without a wearable - Stock Titan
Glucotrack Announces IDE Submission for U.S. Clinical Study of Its Novel Implantable Continuous Blood Glucose Monitoring Technology - Moomoo
GCTK Stock Jumps As Implantable CGM Data Impresses - StocksToTrade
GCTK Jumps As GlucoTrack’s Implantable CGM Data Impresses - timothysykes.com
$Glucotrack (GCTK.US)$ no bad。 sell it now - Moomoo
see if this zone is the one. $Glucotrack (GCTK.US)$ - Moomoo
GCTK SEC FilingsGlucotrack 10-K, 10-Q, 8-K Forms - Stock Titan
Needle-free diabetes care: 6 devices that painlessly monitor blood sugar - Labiotech.eu
GlucoTrack Executes Debt-for-Equity Exchange and Investor Update - The Globe and Mail
GlucoTrack Reports Strong Preclinical Data for Implantable CBGM - The Globe and Mail
Peer-Reviewed Study in Journal of Diabetes Research Verifies Glucotrack’s Long‑Term Continuous Blood Glucose Monitoring Technology - citybiz
[EFFECT] Glucotrack, Inc. SEC Filing - Stock Titan
Glucotrack (NASDAQ: GCTK) swaps $988K debt for 1.3M new shares - Stock Titan
Glucotrack publishes 240-day glucose monitor study results By Investing.com - Investing.com South Africa
Peer-reviewed CBGM data back Glucotrack (NASDAQ: GCTK) IDE plans - Stock Titan
Glucotrack publishes 240-day glucose monitor study results - Investing.com
Glucotrack Inc Stock (GCTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):